Targets › POLR2A
15 programs from 13 companies in 27 trials: 9 Phase 4, 8 Phase 1, 5 Phase 2, 5 Phase 3; Infectious disease, Oncology, Genitourinary; next expected readout Dec 2026.
Catalytic core component of RNA polymerase II (Pol II), a DNA-dependent RNA polymerase which synthesizes mRNA precursors and many functional non-coding RNAs using the four ribonucleoside triphosphates as substrates (By similarity). Pol II-mediated transcription cycle proceeds through transcription initiation, transcription elongation and transcription termination stages. (UniProt, P24928)
Open in Phaseline: the race on POLR2A, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Instituto Mexicano del Seguro Social | Darunavir Human immunodeficiency virus type 1 protease inhibitor | PROT, CYP3A4, POLR2A | Phase 4 | HIV Infection | Dec 2026 |
| Harvard School of Public Health (HSPH) | DTG/ABC/3TC Integrase strand transfer inhibitor (dolutegravir) combined with nucleoside reverse transc | INTEGRASE, ABCC4, POLR2A | Phase 4 | HIV | Dec 2026 |
| Kirby Institute | Sofosbuvir RNA-directed RNA polymerase inhibitor | POLR2A | Phase 4 | Hepatitis C | Jul 2029 |
| Jiangsu Hansoh Pharmaceutical | Tenofovir Amibufenamide (TMF) Nucleotide reverse transcriptase inhibitor (NRTi) - prodrug of tenofovir | POLR2A | Phase 4 | Hepatitis B, Chronic | Sep 2029 |
| José Antonio Mata Marín | DTG/3TC Integrase strand transfer inhibitor (INSTI) + nucleoside reverse transcriptase inhibitor ( | INTEGRASE, POLR2A | Phase 4 | HIV Infections | – |
| Luye Pharma Group | Lurbinectedin RNA polymerase II inhibitor; RNA-dependent transcription inhibitor | POLR2A | Phase 3 | Relapsed Small Cell Lung Cancer | Dec 2027 |
| Gilead Sciences | Emtricitabine Human immunodeficiency virus type 1 reverse transcriptase inhibitor | POLR2A, POLR1C | Phase 3 | Pre-Exposure Prophylaxis of HIV Infection; Hiv; Alcohol Use, Unspecified; Pre-exposure Prophylaxis … | Jan 2028 |
| GSK | RPV ULA Non-nucleoside reverse transcriptase inhibitor (ultra-long-acting formulation) | POLR2A | Phase 3 | HIV Infections | Sep 2029 |
| Africa Health Research Institute | Dapivirine Human immunodeficiency virus type 1 reverse transcriptase inhibitor | POLR2A | Phase 3 | HIV Infections | – |
| Merck & Co. (MSD) | ISL/ULO fixed-dose combination of nucleoside reverse transcriptase translocation inhibitor and non | POLR2A | Phase 2 | Human Immunodeficiency Virus Type 1 (HIV-1) Infection | Feb 2029 |
| Harvard School of Public Health (HSPH) | Nevirapine Human immunodeficiency virus type 1 reverse transcriptase inhibitor | POLR2A | Phase 2 | HIV | Jun 2029 |
| Harvard School of Public Health (HSPH) | Zidovudine Human immunodeficiency virus type 1 reverse transcriptase inhibitor | POLR2A | Phase 2 | HIV | Jun 2029 |
| National Cancer Institute (NCI) | Pidnarulex RNA Polymerase I inhibitor | POLR2A, POLR1A | Phase 1 | Metastatic Malignant Solid Neoplasm; Metastatic Colorectal Adenocarcinoma; Anatomic Stage III Breast Cancer AJCC v8; Burkitt Lymphoma | Dec 2026 |
| Senhwa Biosciences | CX-5461 POLR2A/POLR1A inhibitor; transcription inhibitor targeting ribosomal RNA synthesis | POLR2A, POLR1A | Phase 1 | Advanced Solid Tumor | Mar 2027 |
| Henan Genuine Biotech | Ro-0622 Reverse transcriptase inhibitor; Replicase polyprotein 1ab inhibitor; Human immunodeficiency virus type 1 reverse transcriptase inhibitor | POLR2A | Phase 1 | Renal Insufficiency | – |
HIV Infections (3) HIV (3) HIV Infection (2) Pre-Exposure Prophylaxis of HIV Infection (2) Metastatic Malignant Solid Neoplasm (1) Metastatic Colorectal Adenocarcinoma (1) Anatomic Stage III Breast Cancer AJCC v8 (1) Burkitt Lymphoma (1) Renal Insufficiency (1) Advanced Solid Tumor (1) Relapsed Small Cell Lung Cancer (1) Hepatitis B, Chronic (1)
small molecule (14), mixed (1)
Harvard School of Public Health (HSPH) (3) Instituto Mexicano del Seguro Social (1) José Antonio Mata Marín (1) National Cancer Institute (NCI) (1) Henan Genuine Biotech (1) Senhwa Biosciences (1) Luye Pharma Group (1) GSK (1) Jiangsu Hansoh Pharmaceutical (1) Kirby Institute (1) Gilead Sciences (1) Africa Health Research Institute (1) Merck & Co. (MSD) (1)
INTEGRASE (2) POLR1A (2) PROT (1) CYP3A4 (1) POLR1C (1) ABCC4 (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.